Dauntless Investment Group’s INmune Bio INMB Stock Holding History

Dauntless Investment Group’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$207K	Sell	183,476 -121,446	-40%	-$173K	0.14%	45
2025 Q4	$476K	Buy	+304,922	New	+$544K	0.38%	35
2025 Q3	–	Sell	-248,542	Closed	-$311K	–	87
2025 Q2	$311K	Buy	248,542 +117,862	+90%	+$865K	0.54%	31
2025 Q1	$1.02M	Sell	130,680 -61,142	-32%	-$486K	1.19%	16
2024 Q4	$896K	Buy	+191,822	New	+$1M	0.94%	15

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dauntless Investment Group's INMB Position: Q1 2026 in Review

Dauntless Investment Group reduced its INmune Bio (INMB) stake by 40% in Q1 2026, selling an estimated $173K and leaving 183,476 shares worth $207K. The position accounts for 0.14% of the portfolio, ranked #45.

Dauntless Investment Group first reported a position in INMB in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.02M in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

Dauntless Investment Group held 183,476 shares of INmune Bio worth $207K as of Q1 2026.
Dauntless Investment Group sold 121,446 INmune Bio shares in Q1 2026, an estimated $173K.
INmune Bio made up 0.14% of Dauntless Investment Group's portfolio in Q1 2026, its #45 holding.
Dauntless Investment Group first reported a position in INmune Bio in Q4 2024 and has held it in 5 quarters since.
Dauntless Investment Group's INmune Bio position peaked at $1.02M in Q1 2025.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Dauntless Investment Group's 13F filing for Q1 2026, filed 14 May 2026.